|
KMID : 0378019950380080062
|
|
New Medical Journal
1995 Volume.38 No. 8 p.62 ~ p.68
|
|
|
Efficacy and Safety of Inhaled Salmeterol in the Treatment of Adult Patients with Mild to Moderate Bronchial Asthma
|
|
|
|
|
Abstract
|
|
|
Currently available t2 adrenoreceptor agonists have a short duration of effect of 4-6 hours, with a resultant need for four times daily dosing to achieve effective bronchodilatation. Salmeterol is a selective inhaled t2 adrenoreceptor agonist It has been shown in animal experiments to produce a more prolonged bronchodilator effect than currently available R2 adrenoreceptor agonists. It also provides protection against histamine-induced bronchoconstriction in healthy subjects for at least 12 hours. We designed the study to evaluate the efficacy and safety of 50pg inhaled salmeterol twice daily in thirty adult patients with mild to moderate asthma on PEFR, day-time asthma symptom score, night-time asthma symptom score, FEV1, FVC and use of rescue medication. Our study is an open study consisting of a treatment period of 10 weeks duration. The treatment period was preceded by two run-in periods of one-week duration and followed by a 2 week follow-up periods. Separate analysis was performed during treatment that is, first half 5 weeks and second half 5 weeks.
The results were as follows ;
1. Five weeks and ten weeks after administration of 50pg inhaled salmeterol twice daily, there was a significant increase in day time PEFR than end of run-in periods, but there were significant differences in night time PEFR.
2. There was no significant increase in FVC but a significant increase in FEV I after salmeterol treatment.
3. Day time symptom score showed significant improvement after salmeterol treatment, but there were no significant differences in night-time score, percentage of days with symptom score-0 and the number of days required for additional bronchodilator compared end of run-in periods.
4. There was no adverse reactions requiring to quit the salmeterol study.
In conclusion, salmeterol has an effect on improvement of PEFR, FEVI and symptom score and is effective in the management of adult patients with mild to moderate bronchial asthma.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|